Pfizer and BioNTech start trials of new Omicron-specific jab

Pfizer and BioNTech have started clinical trials of a new Covid vaccine that targets the Omicron variant.

The companies plan to test the protection gained from the new vaccine as a booster jab and as three separate jabs in unvaccinated people.

BBC News reports more than 1,400 adults are expected to be enrolled in the trial, likely to be in the United States.

US company Moderna is planning to begin trials of its own Omicron-specific vaccine soon.

Oxford University and AstraZeneca have also started working on a new version of their vaccine.

[Source: BBC ]